Molecularly, ABC-DLBCL frequently harbors co-occurring mutations in MYD88, CD79A/B, CDKN2A, and TNFAIP3, which converge on chronic NF-κB pathway activation [4]. Here, MYD88 is linked to diffuse large B-cell lymphoma.